Work

Bortezomib is active as a single agent against multidrug resistant (MDR) leukemia in vitro but does not synergize with cytarabine (Ara-C), daunorubicin (DNR), doxorubicin (Dox) or Idarubicin (Ida).

Year: 2006

Type: article

Source: Cancer Research

Authors: Hans Minderman, Kieran L. O’Loughlin, Maria R. Baer

Institution: Roswell Park Comprehensive Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1514175189

FWCI:

Cites:

Cited by:

Related to: 10